Printer Friendly

Eusa Pharma purchases global Sylvant rights from Janssen Sciences Ireland.

M2 EQUITYBITES-January 11, 2019-Eusa Pharma purchases global Sylvant rights from Janssen Sciences Ireland


Eusa Pharma, a biopharmaceutical company, has purchased the global rights to Sylvant (siltuximab), a drug for the treatment of idiopathic multicentric Castleman's disease (iMCD) from Janssen Sciences Ireland, it was reported yesterday.

The deal is valued at USD115m. The firm is planning to re-launch Sylvant across the US during this month, and is currently training a team of 30 specialist oncology representatives and medical science liaisons to better market the treatment.

The drug has received approval in more than 40 countries to treat iMCDe, which is a subtype of Castleman disease or giant lymph node hyperplasia, lymphoid hamartoma, or angiofollicular lymph node hyperplasia. The product is a monoclonal antibody that inhibits the action of interleukin-6 (IL-6), a multifunctional cytokine detected at elevated levels in iMCD patients. It is claimed to be the only approved treatment for iMCD in the US. Eusa Pharma aims to commercialise Sylvant through its global commercial platform, allowing it to expand the treatment into new markets.

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jan 11, 2019
Previous Article:Elevian signs research and development collaboration with Insilico Medicine.
Next Article:Selexis expands collaboration with Agenus.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters